Hints and tips:
...He initially showed little interest in megamergers of the kind Pfizer carried out in the prior decade with Wyeth and Warner-Lambert....
...That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth....
...Yet no amount of marketing could make up for the dearth of new medicines coming out of Pfizer’s laboratories....
...At the heart of debate over the future of AstraZeneca is a simple question: In whose hands would the pharmaceutical company’s laboratories produce the most valuable drugs?...
...In the five years since Pfizer bought Wyeth, it has cut about half the total research and development spending made by the two companies the year before the deal....
...For Pfizer, a deal would add to its history of megamergers, including its $69bn takeover of Wyeth in 2009 and its $111.8bn deal with Warner-Lambert in 2000....
...But much recent activity has instead focused on divestments, including spinoffs by Pfizer in the wake of its Wyeth purchase and by GlaxoSmithKline of some consumer products....
...Those included advice on the design and writing up of clinical drug trials and adding their names and credibility to articles ghost-written by specialist authors hired by the companies....
...For example, one rationale behind Pfizer’s takeover of Wyeth last year was to defer the pain of patent expiries....
...Pfizer last year paid $68bn to acquire its smaller US rival Wyeth, while Abbott Laboratories of the US bought Solvay of Belgium’s pharmaceuticals business for $6.5bn....
...Forest Laboratories’ UK division bought the Bisodol brand of indigestion products from Wyeth in 2004 and acquired the 70-year old nappy-rash treatment Sudocrem when it bought the Irish company Tosara in...
...Leader of the pack is a San Diego company, Brain Cells Inc , founded by academics from Salk and Columbia....
...Abbott Laboratories on Monday announced the €4.5bn ($6.6bn) acquisition of Solvay’s pharmaceutical company, bringing a five-month takeover battle to an end and highlighting continued consolidation in the...
...Last year brought an extraordinary range of mega-mergers, with Pfizer paying $68bn (£45bn, €50bn) for Wyeth, Merck $41bn for Schering-Plough, and Roche spending $47bn to buy out the minority shareholders...
...Abbott Laboratories of the US has edged ahead of UCB of Belgium and Nycomed of Switzerland in the contest, according to people close to the situation....
...Monday’s deals follow Pfizer’s agreement earlier this year to acquire Wyeth, what the Journal terms one of the relatively few big pharma companies known for its vaccine expertise....
...Solvay has whittled down the list of bidders for its pharmaceuticals business to Nycomed, the privately held Swiss company, and Abbott Laboratories of the US....
...Cost cutting in the wake of recent deals, such as Pfizer’s $68bn purchase of Wyeth and Merck’s $41bn takeover of Schering-Plough, will help offset the fall in revenues as drug patents expire....
...GlaxoSmithKline, the pharmaceutical group, has agreed to pay up to $3.6bn (£2.5bn) for Stiefel Laboratories of the US, significantly boosting its presence in dermatology as part of a growing portfolio of...
...The purchase of Stiefel Laboratories for up to $3.6bn (£2.5bn) is the largest deal he has yet conducted....
...To his astonishment, they invited the academic outsider on a site visit to their new laboratories in Alderley Edge. “They said it would be much easier if I did the work in their labs....
...The five big pharmaceuticals companies most affected by such concerns are Pfizer, Merck, Wyeth, Eli Lilly and Bristol-Myers Squibb....
...The park is now thriving as a centre of excellence, with more than 530,000 sq ft of office and laboratory space....
...Successes in this category include Humira, discovered by Cambridge Antibody Technology (CAT) in the UK and developed by Abbott in the US, and Enbrel from Amgen and Wyeth....
...Warner Chilcott, which was involved in aborted takeover talks last year with Barr Laboratories of the US, said the approach was at a preliminary stage and there was no guarantee an offer would be made....
International Edition